Multiple Myeloma
Ide-cel vs Standard Regimens for Patients With Relapsed and Refractory Multiple Myeloma
You're currently viewing OncGenius as a guest. To save your results, create an account or log in.
Advertisement
Ide-cel vs Standard Regimens for Patients With Relapsed and Refractory Multiple Myeloma
ASH 2022: Talquetamab for Relapsed or Refractory Multiple Myeloma
Patients With Multiple Myeloma Receiving Salvage Treatment After BCMA-Directed CAR T-Cell Therapy
ASCO 2022: Adding ASCT to Triplet/Maintenance Therapy for Newly Diagnosed Multiple Myeloma
Combined BCMA and CD19 CAR T-Cells in Relapsed or Refractory Multiple Myeloma